Skip to main content
Top
Published in: Diabetologia 12/2007

01-12-2007 | Article

Within-subject variability of measures of beta cell function derived from a 2 h OGTT: implications for research studies

Authors: K. M. Utzschneider, R. L. Prigeon, J. Tong, F. Gerchman, D. B. Carr, S. Zraika, J. Udayasankar, B. Montgomery, A. Mari, S. E. Kahn

Published in: Diabetologia | Issue 12/2007

Login to get access

Abstract

Aims/hypothesis

Knowledge of the within-subject variability of a parameter is required to properly design and calculate sample sizes for longitudinal studies. We sought to determine the day-to-day variability of measures of beta cell function derived from an OGTT.

Methods

Thirty-seven adults (13 with normal glucose tolerance, ten with impaired glucose tolerance, 14 with type 2 diabetes) underwent a standard 2 h 75 g OGTT on two separate days (median time between tests, 7 days; range, 5–14). From these data, the reproducibility of several indices of beta cell function were determined: insulinogenic index (ΔI0–30/ΔG0–30), early C-peptide response (ΔCP0–30/ΔG0–30), incremental AUC insulin to glucose response (incAUCins/incAUCglu), integrated insulin secretion response from 0 to 120 min (IS/Glu0–120) and indices of beta cell function derived from a mathematical model.

Results

Within-subject variability for ΔI0–30/ΔG0–30 (CV 57.1%) was higher than ΔCP0–30/ΔG0–30 (CV 34.7%). Measures integrated over the full 120 min of the OGTT, incAUCins/incAUCglu (CV 24.9%) and IS/Glu0–120 (CV 17.4%), demonstrated less variability. The mathematical model-derived measures of beta cell glucose sensitivity (CV 20.3%) and potentiation (CV 33.0%) showed moderate variability. The impact of the different measures’ variability on sample size (30% change from baseline) is demonstrated by calculated sample sizes of 89 for ΔI0–30/ΔG0–30, 37 for ΔCP0–30/ΔG0–30, 21 for incAUCins/incAUCglu and 11 for IS/Glu0–120.

Conclusions/interpretation

Some OGTT-derived indices of beta cell function, in particular the insulinogenic index, demonstrate high within-subject variability. Integrated measures that utilise multiple time points and measures that use C-peptide show less variability and may lead to a reduced sample size requirement.
Literature
1.
go back to reference Mooy JM, Grootenhuis PA, de Vries H et al (1996) Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. Diabetologia 39:298–305CrossRefPubMed Mooy JM, Grootenhuis PA, de Vries H et al (1996) Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. Diabetologia 39:298–305CrossRefPubMed
2.
3.
go back to reference Harding PE, Oakley NW, Wynn V (1973) Reproducibility of oral glucose tolerance data in normal and mildly diabetic subjects. Clin Endocrinol (Oxf) 2:387–395 Harding PE, Oakley NW, Wynn V (1973) Reproducibility of oral glucose tolerance data in normal and mildly diabetic subjects. Clin Endocrinol (Oxf) 2:387–395
4.
go back to reference Wolever TM, Chiasson JL, Csima A et al (1998) Variation of postprandial plasma glucose, palatability, and symptoms associated with a standardized mixed test meal vs 75 g oral glucose. Diabetes Care 21:336–340CrossRefPubMed Wolever TM, Chiasson JL, Csima A et al (1998) Variation of postprandial plasma glucose, palatability, and symptoms associated with a standardized mixed test meal vs 75 g oral glucose. Diabetes Care 21:336–340CrossRefPubMed
5.
go back to reference Morgan C, Lazarow A (1963) Immunoassay of insulin: two antibody systems. Diabetes 12:115–126 Morgan C, Lazarow A (1963) Immunoassay of insulin: two antibody systems. Diabetes 12:115–126
6.
go back to reference Van Cauter E, Mestrez F, Sturis J, Polonsky KS (1992) Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 41:368–377CrossRefPubMed Van Cauter E, Mestrez F, Sturis J, Polonsky KS (1992) Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 41:368–377CrossRefPubMed
7.
go back to reference Mari A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B, Ferrannini E (2002) Meal and oral glucose tests for assessment of β-cell function: modeling analysis in normal subjects. Am J Physiol Endocrinol Metab 283:E1159–E1166PubMed Mari A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B, Ferrannini E (2002) Meal and oral glucose tests for assessment of β-cell function: modeling analysis in normal subjects. Am J Physiol Endocrinol Metab 283:E1159–E1166PubMed
8.
go back to reference Levy JC, Matthews DR, Hermans MP (1998) Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21:2191–2192CrossRefPubMed Levy JC, Matthews DR, Hermans MP (1998) Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21:2191–2192CrossRefPubMed
9.
go back to reference Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ (2001) A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 24:539–548CrossRefPubMed Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ (2001) A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 24:539–548CrossRefPubMed
10.
go back to reference Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462–1470CrossRefPubMed Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462–1470CrossRefPubMed
11.
go back to reference Stumvoll M, Mitrakou A, Pimenta W et al (2000) Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 23:295–301CrossRefPubMed Stumvoll M, Mitrakou A, Pimenta W et al (2000) Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 23:295–301CrossRefPubMed
12.
go back to reference van Belle G, Martin DC (1993) Sample size as a function of coefficient of variation and ratio of means. Am Stat 47:165–167CrossRef van Belle G, Martin DC (1993) Sample size as a function of coefficient of variation and ratio of means. Am Stat 47:165–167CrossRef
13.
go back to reference Efron B, Tibshirani R (1993) An introduction to the bootstrap. Chapman & Hall/CRC, Boca Raton Efron B, Tibshirani R (1993) An introduction to the bootstrap. Chapman & Hall/CRC, Boca Raton
14.
go back to reference Abbate SL, Fujimoto WY, Brunzell JD, Kahn SE (1993) Effect of heparin on insulin-glucose interactions measured by the minimal model technique: Implications for reproducibility using this method. Metabolism 42:353–357CrossRefPubMed Abbate SL, Fujimoto WY, Brunzell JD, Kahn SE (1993) Effect of heparin on insulin-glucose interactions measured by the minimal model technique: Implications for reproducibility using this method. Metabolism 42:353–357CrossRefPubMed
15.
go back to reference Schousboe K, Henriksen JE, Kyvik KO, Sorensen TI, Hyltoft Petersen P (2002) Reproducibility of S-insulin and B-glucose responses in two identical oral glucose tolerance tests. Scand J Clin Lab Invest 62:623–630CrossRefPubMed Schousboe K, Henriksen JE, Kyvik KO, Sorensen TI, Hyltoft Petersen P (2002) Reproducibility of S-insulin and B-glucose responses in two identical oral glucose tolerance tests. Scand J Clin Lab Invest 62:623–630CrossRefPubMed
16.
go back to reference Mari A, Nielsen LL, Nanayakkara N, Defronzo RA, Ferrannini E, Halseth A (2006) Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea. Horm Metab Res 38:838–844CrossRefPubMed Mari A, Nielsen LL, Nanayakkara N, Defronzo RA, Ferrannini E, Halseth A (2006) Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea. Horm Metab Res 38:838–844CrossRefPubMed
17.
go back to reference Mari A, Gastaldelli A, Foley JE, Pratley RE, Ferrannini E (2005) Beta-cell function in mild type 2 diabetic patients: Effects of 6-month glucose lowering with nateglinide. Diabetes Care 28:1132–1138CrossRefPubMed Mari A, Gastaldelli A, Foley JE, Pratley RE, Ferrannini E (2005) Beta-cell function in mild type 2 diabetic patients: Effects of 6-month glucose lowering with nateglinide. Diabetes Care 28:1132–1138CrossRefPubMed
18.
go back to reference Kahn SE, Prigeon RL, McCulloch DK et al (1993) Quantification of the relationship between insulin sensitivity and β-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 42:1663–1672CrossRefPubMed Kahn SE, Prigeon RL, McCulloch DK et al (1993) Quantification of the relationship between insulin sensitivity and β-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 42:1663–1672CrossRefPubMed
19.
go back to reference Valdes CT, Elkind-Hirsch KE (1991) Intravenous glucose tolerance test-derived insulin sensitivity changes during the menstrual cycle. J Clin Endocrinol Metab 72:642–646PubMedCrossRef Valdes CT, Elkind-Hirsch KE (1991) Intravenous glucose tolerance test-derived insulin sensitivity changes during the menstrual cycle. J Clin Endocrinol Metab 72:642–646PubMedCrossRef
Metadata
Title
Within-subject variability of measures of beta cell function derived from a 2 h OGTT: implications for research studies
Authors
K. M. Utzschneider
R. L. Prigeon
J. Tong
F. Gerchman
D. B. Carr
S. Zraika
J. Udayasankar
B. Montgomery
A. Mari
S. E. Kahn
Publication date
01-12-2007
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 12/2007
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-007-0819-5

Other articles of this Issue 12/2007

Diabetologia 12/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.